Arecor Therapeutics - Final Results for the Year Ended 31 December 2024
•    Focus on high value R&D underpinned by Arestat™ technology and Company expertise positions Arecor for significant future growth and success
•    Significant advancements in diabetes portfolio with positive progress towards strategic partnership for AT278
•    Potential to unlock significant value through innovation in the oral delivery of peptides
•    Growing revenue stream from AT220 global royalties